AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

AstraZeneca (NASDAQ:AZN) has reached a significant milestone with the U.S. approval of its drug Imfinzi for adult patients ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

Discover how a TB vaccine could revolutionise bladder cancer treatment. Find out more about this groundbreaking study.

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly improve patient outcomes for ...

"We were particularly pleased to see that these results are further supported by an exploratory sub-analysis including only ...

Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...